Merck KGaA Earnings Call: Resilient Year, Tough 2026

Merck KGaA Sponsored ADR ((MKKGY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Merck KGaA’s latest earnings call painted a picture of a company holding its ground in choppy markets. Management stressed resilient organic growth, solid cash generation and clear strategic progress, even as currency headwinds, product life‑cycle pressures and regulatory uncertainties weighed on near‑term visibility and turned 2026 into a transition year.

Delivered on 2025 Targets

Merck confirmed it hit its 2025 guidance, with group net sales broadly stable at EUR 21.1 billion and EBITDA pre at EUR 6.1 billion. That equates to a healthy 28.9% margin, underscoring disciplined cost control and operational resilience despite external headwinds.

Profitable Organic EBITDA Growth

Underlying profitability improved, with group EBITDA pre growing 5.6% organically for the full year. This shows the business expanding earnings even as reported numbers were dampened by foreign exchange and a mixed macro backdrop.

Q4 Momentum Across Sectors

In Q4 2025, organic group sales rose 2.6% and EBITDA pre increased 3.1% organically. Management highlighted that all three sectors contributed to the quarter, suggesting momentum into 2026 despite looming challenges.

Life Science Returns to Growth

Life Science delivered a 4% organic sales increase in 2025 as demand normalized, with Process Solutions posting double‑digit organic growth. EBITDA pre in the division rose 3.9% organically, keeping margins at an attractive 28.8% for the year.

Healthcare Delivers Double-Digit EBITDA Growth

Healthcare net sales grew 3.7% organically in 2025, powered by a 7% organic increase in CM&E. The sector’s EBITDA pre climbed more than 11% organically to EUR 3.0 billion, with fertility products and Mavenclad posting double‑digit growth in the fourth quarter.

Semiconductor Materials Lead Electronics

Electronics saw its semiconductor materials business deliver its strongest quarter in Q4 and high single‑digit organic growth for the year. AI‑driven demand and advanced chip nodes were key tailwinds, supported by the inauguration of a EUR 500 million Semiconductor Solutions megasite in Taiwan.

Active M&A and Portfolio Reshaping

Merck accelerated portfolio moves, closing the SpringWorks deal to build a rare‑diseases growth pillar and acquiring Unity‑SC to strengthen inspection capabilities. It also agreed to sell Surface Solutions to sharpen Electronics as a pure‑play semiconductor business and added JSR chromatography and HUB Organoids to boost Life Science.

Heavy Investment in Global Footprint

Over recent years, the company has invested more than EUR 7 billion in over 30 new or expanded sites worldwide. A EUR 100 million facility in Blarney, Ireland, and further region‑for‑region investments highlight a strategy of building local capacity close to customers.

Commitment to Shareholder Returns

Reflecting solid cash flows and disciplined capital allocation, the board plans to propose a stable dividend of EUR 2.20 per share. Management framed this as balancing shareholder returns with continued investment in strategic growth projects.

Foreign Exchange Remains a Major Drag

Currency movements created roughly a 4% headwind on 2025 net sales and weighed on EBITDA pre, masking stronger underlying trends. Merck warned that FX will stay negative and volatile in 2026, with an especially heavy impact expected in the first quarter.

Mavenclad Patent Cliff in the U.S.

A key challenge is the imminent U.S. loss of exclusivity for Mavenclad, a major multiple sclerosis drug. Guidance assumes no U.S. Mavenclad sales from March 2026, turning 2026 into a transition year for Healthcare as it absorbs a sizeable revenue and profit hit.

Electronics DS&S Under Pressure

Electronics posted a slight full‑year organic decline of 0.6%, as the DS&S business suffered from prolonged delays in large customer projects. Sector EBITDA pre fell 9%, partly due to one‑off Q2 items, tempering the otherwise strong performance in semiconductor materials.

Guidance Bakes in Downside Scenarios

For 2026, management guided to group net sales of EUR 20.0–21.1 billion and EBITDA pre of EUR 5.5–6.0 billion. The range implies flat to modest organic sales growth but allows for lower absolute earnings versus 2025 if macro, FX and portfolio headwinds bite.

Regulatory and Product Launch Uncertainty

The timing and impact of the Pergoveris U.S. launch remain unclear and are excluded from 2026 guidance. Management also noted an evolving regulatory environment and changing requirements, which complicate planning and may delay potential upside from new products.

CDMO Strategy Still Under Review

Merck’s strategic review of its CDMO business is still in progress, with no final decision communicated. Investors are left waiting to see whether the company will double down, restructure or divest, which could materially reshape the portfolio.

Geopolitics and Trade Frictions as Risk Factors

Management flagged geopolitical tensions, including developments in the Middle East, as ongoing operational risks, though no material impact has been seen so far. Tariff complexity also remains an overhang, with some Life Science and Electronics imports hit by U.S. duties despite a temporary pharmaceutical exemption.

Guidance and Outlook

Looking ahead, Merck expects 2026 organic sales to range from a 1% decline to 2% growth and EBITDA pre between EUR 5.5–6.0 billion. Life Science should deliver mid‑single‑digit organic growth, while Healthcare absorbs Mavenclad pressure and Electronics benefits from strong semiconductor demand as DS&S stabilizes.

Merck’s earnings call showed a company balancing resilience and reset, with strong Life Science and semiconductor momentum offset by FX, DS&S softness and a looming Mavenclad cliff. Strategic M&A, heavy capex and a steady dividend underpin a medium‑term growth story, but investors should brace for a bumpy 2026 transition year.